



AKUMS DRUGS AND PHARMACEUTICALS LIMITED



(Please scan this QR code to view the RHP)

Our Company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of 'Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi ("RoC"). Our Company received a certificate of commencement of business issued by the RoC dated May 13, 2004. For details of changes in the name and the registered office address of our Company, please see section titled "History and Certain Corporate Matters" on page 247 of the Prospectus dated August 1, 2024 ("Prospectus").

Registered Office: 304, Mohan Place, LSC Saraswati Vihar, Delhi - 110 034, India, Corporate Office: Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase-1, Delhi 110 083, India
Telephone: + 91 11 6904 1000; Contact person: Dharamvir Malik, Company Secretary and Compliance Officer, E-mail: cs@akums.net; Website: www.akums.in; Corporate Identity Number: U24239DL2004PLC125888

THE COMMENCEMENT OF TRADING OF THE EQUITY SHARES OF OUR COMPANY ON THE STOCK EXCHANGES SHALL BE WITH EFFECT FROM AUGUST 06, 2024. THE COMMENCEMENT OF TRADING OF THE EQUITY SHARES OF OUR COMPANY SHALL BE ON T+3 DAY (T BEING THE ISSUE CLOSING DATE) IN TERMS OF THE TIMELINES PRESCRIBED UNDER THE SEBI CIRCULAR NO. SEBI/HO/CFD/TPD1/CIR/P/2023/140 DATED AUGUST 09, 2023, WHICH REDUCED THE TIMELINE FOR LISTING OF EQUITY SHARES IN PUBLIC ISSUE FROM EXISTING T+6 DAYS TO T+3 DAYS.

THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST

Our Company has filed the Prospectus with the RoC and the Equity Shares are proposed to be listed on the Main Board of the National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") and the trading will commence on August 6, 2024.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 27,368,151* EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH ("EQUITY SHARES") OF AKUMS DRUGS AND PHARMACEUTICALS LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ 679* PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 677 PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING TO ₹ 18,567.37 MILLION** COMPRISING A FRESH ISSUE OF 10,037,716* EQUITY SHARES AGGREGATING TO ₹ 6,800.00** MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF 17,330,435 EQUITY SHARES AGGREGATING TO ₹ 11,767.37 MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS, COMPRISING OF 1,512,000 EQUITY SHARES AGGREGATING TO ₹ 1,026.65 MILLION* BY SANJEEV JAIN, 1,512,000 EQUITY SHARES AGGREGATING TO ₹ 1,026.65 MILLION* BY SANDEEP JAIN (TOGETHER THE "PROMOTER SELLING SHAREHOLDERS") AND 14,306,435 EQUITY SHARES AGGREGATING TO ₹ 9,714.07 MILLION* BY RUBY QC INVESTMENT HOLDINGS PTE. LTD. (THE "INVESTOR SELLING SHAREHOLDER") (THE PROMOTER SELLING SHAREHOLDERS AND THE INVESTOR SELLING SHAREHOLDER, COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") ("OFFER FOR SALE", TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

THIS OFFER INCLUDES A RESERVATION OF 243,902* EQUITY SHARES AGGREGATING TO ₹ 150.00 MILLION** FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER CONSTITUTED 17.39% AND 17.23% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL, RESPECTIVELY.

THE FACE VALUE OF EQUITY SHARES IS ₹ 2 EACH. THE OFFER PRICE IS 339.50 TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WAS DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WAS ADVERTISED IN ALL EDITIONS OF FINANCIAL EXPRESS, AN ENGLISH NATIONAL DAILY NEWSPAPER AND ALL EDITIONS OF JANSATTA, A HINDI NATIONAL DAILY NEWSPAPER (HINDI ALSO BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS LOCATED), EACH WITH WIDE CIRCULATION, AND WAS MADE AVAILABLE TO BSE AND NSE (TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES.

DETAILS OF THE OFFER FOR SALE

Name of Selling Shareholder	Type	NUMBER OF EQUITY SHARES OFFERED*	WEIGHTED AVERAGE COST OF ACQUISITION (IN ₹ PER EQUITY SHARE)**
Sanjeev Jain	Promoter Selling Shareholder	1,512,000 Equity Shares of face value of ₹ 2 each aggregating to ₹ 1,026.65 million	Negligible
Sandeep Jain	Promoter Selling Shareholder	1,512,000 Equity Shares of face value of ₹ 2 each aggregating to ₹ 1,026.65 million	Negligible
Ruby QC Investment Holdings Pte. Ltd.	Investor Selling Shareholder	14,306,435 Equity Shares of face value of ₹ 2 each aggregating up ₹ 9,714.07 million	231.64

*Subject to finalisation of Basis of Allotment. | **As certified by T A M S & CO LLP, Chartered Accountants by way of their certificate dated August 1, 2024.

CORRIGENDUM - NOTICE TO INVESTOR

Due to inadvertent typographical error, the date of the tripartite agreement entered between our Company, Registrar to the Offer and NSDL has been mentioned in the DRHP, RHP and Prospectus, but the date of execution of the agreement is August 2, 2019.

ANCHOR INVESTOR OFFER PRICE:
₹679 PER EQUITY SHARE OF FACE VALUE OF ₹2 EACH

OFFER PRICE:
₹679 PER EQUITY SHARE OF FACE VALUE OF ₹2 EACH

THE OFFER PRICE IS 339.50 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

RISK TO INVESTORS

- Concentration of manufacturing units:** Our manufacturing units and research and development centres are concentrated in Haridwar, Uttarakhand and we are exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could have an adverse effect on our business operations.
- Third party dependence for raw materials:** We rely on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could have an adverse effect on our business operations.

Particulars	For the Financial Year					
	2024		2023		2022	
	(₹ in millions)	% of total purchases of raw materials	(₹ in millions)	% of total purchases of raw materials	(₹ in millions)	% of total purchases of raw materials
Domestic sourcing	18,331.71	88.11	17,456.85	89.77	21,461.70	88.98
Direct imports	2,473.08	11.89	1,988.80	10.23	2,658.04	11.02

- Fluctuation in financial ratios:** Our EBITDA margin, profit after tax margin, return on equity and return on capital employed have fluctuated significantly during the Financial Years 2024, 2023 and 2022.

Particulars	For the Financial Year		
	2024	2023	2022
EBITDA margin (%)	3.73	10.38	(1.87)
Profit after tax margin (%)	0.02	2.64	(6.79)
Return on equity (%)	0.11	13.52	(40.13)
Return on capital employed (%)	3.37	24.60	(18.89)

- Negative Cash Flows:** We have had negative cash flows from investing activities during the Financial Year 2024. Negative cash flows over extended periods, or significant negative cash flows in the short term, could affect our ability to operate our business and implement our growth plans.

Particulars	For the Financial Year		
	2024	2023	2022
	(₹ in millions)		
Net cash generated from operating activities	4,982.59	1,766.31	318.54
Net cash (used in) investing activities	(3,304.15)	(3,047.02)	(2,348.22)
Net cash (used in) / generated from financing activities	(1,080.21)	1,245.40	2,360.40
Net increase/ (decrease) in cash and cash equivalents	598.23	(35.31)	330.72

- Regulatory Risk:** We have received various notices from regulatory authorities in India alleging instances of non-compliances, including with respect to certain violations of Companies Act, Employees' Provident Fund and Miscellaneous Provisions Act, 1952, Drugs and Cosmetics Act, 1940 and other applicable law by our Company and Subsidiaries in the past. Failure to defend these proceedings successfully could have an adverse effect on our business operations and resultantly, our financial condition.

- Customer Concentration:** Our business is dependent on the sale of products to a limited number of clients for a significant portion of our revenues. The loss of one or more such clients or the deterioration of their financial condition or prospects could adversely affect our business operations.

The revenue contribution of the ten largest clients of our CDMO business for the Financial Years 2024, 2023 and 2022 is ₹12,841.14 million, ₹10,597.55 million and ₹10,982.66 million constituting 39.31%, 38.92% and 41.27% of revenue from operations from CDMO business respectively.

- Manage inventory:** Our inability to accurately forecast demand for our products and manage our inventory may have an adverse effect on our business, results of operations, financial condition and cash flows:

Potential Bidders may note the following:

On May 16, 2024, the individual Promoters of our Company, namely, Sanjeev Jain and Sandeep Jain ("Individual Promoters"), transferred 32,100,000 Equity Shares each to the Akums Master Trust ("Transfer"), which was formed pursuant to a trust deed dated February 7, 2024, wherein the Individual Promoters are also the trustees of the Akums Master Trust. The details of the Transfer are provided below:

Sr. No.	Date of the transfer	Name of the transferor	Name of the transferee	Nature of transfer	Number of Equity Shares transferred	Face Value per Equity Share (₹)	Transfer price per Equity Share (₹)
1.	May 16, 2024	Sanjeev Jain	Akums Master Trust	Gift	32,100,000	2	Nil
2.	May 16, 2024	Sandeep Jain	Akums Master Trust	Gift	32,100,000	2	Nil

Particulars	As of March 31,					
	2024		2023		2022	
	(₹ in millions)	% of total assets	(₹ in millions)	% of total assets	(₹ in millions)	% of total assets
Inventories	6,304.25	17.93	7,297.95	22.34	7,224.48	23.54

- Our Company had issued Equity Shares to more than 49 investors in the past, which may have been in non-compliance with the Companies Act, 1956.
- Significant capital expenditure requirement:** Our business requires significant capital expenditure. If we are unable to have access to capital, it could have an adverse effect on our business operations. The capital expenditure incurred by us for our CDMO business in Fiscals 2024, 2023 and 2022 is ₹2,994.12 million, ₹2,879.10 million and ₹1,970.12 million respectively.
- Export Risk:** We export our products to regulated and semi-regulated markets and a failure to comply with the regulatory and other requirements of such markets could have an adverse effect on our business operations.
- Operation Risk:** Any slowdown or shutdown in our manufacturing and research and development operations could have an adverse effect on our business operations.
- Missing corporate records:** Certain of our corporate records, filings and instruments of transfer are not traceable. We cannot assure you that no legal proceedings or regulatory actions will be initiated against us in the future in relation to any such discrepancies.
- Incurred losses in past:** We have incurred losses in the past and may incur losses in the future.

Particulars	For the Financial Year		
	2024	2023	2022
	(₹ in millions)		
Profit/(loss) for the year	7.90	978.17	(2,508.74)

- Delays in payment of statutory dues:** There have been certain instances of delays in payment of statutory dues by our Company and our Subsidiary in the past. Any failure or delay in payment of such statutory dues may expose us to statutory and regulatory action, as well as significant penalties, and could have an adverse effect on our business operations and resultantly, our financial condition.
- Weighted average cost of acquisition of all shares transacted in the last one year, eighteen months and three years preceding the date of the RHP.

Period	Weighted Average Cost of Acquisition (in ₹)	Cap Price is 'X' times the Weighted Average Cost of Acquisition ^A	Range of acquisition price: Lowest Price - Highest Price (in ₹) ^B
Last 1 year	Nil	N.A.	Nil
Last 18 months	Nil	N.A.	Nil
Last 3 years	Nil	N.A.	Nil

^AAs certified by T A M S & CO LLP, Chartered Accountants pursuant to their certificate dated July 24, 2024.

^BTo be updated in the Prospectus following finalisation of Cap Price, as per the finalised Price Band.

^CExcluding gift and bonus transactions.

- The 4 BRLMs associated with the Issue have handled 69 public issues in the past 3 years, out of which 15 issues have closed below the offer price on the listing date.

Name of the BRLMs	Total Issues	Issues closed below IPO price on listing date
ICICI Securities Limited*	24	5
Axis Capital Limited*	17	4
Citigroup Global Markets India Private Limited*	5	0
Ambit Private Limited*	2	0
Common Issues handled by the BRLMs	21	6
Total	69	15

*Issues handled where there were no common BRLMs.

...continued from previous page.

BID/OFFER PROGRAMME

ANCHOR INVESTOR BID/OFFER PERIOD OPENED AND CLOSED ON: MONDAY, JULY 29, 2024

BID/OFFER OPENED ON: TUESDAY, JULY 30, 2024

BID/OFFER CLOSED ON: THURSDAY, AUGUST 01, 2024

The Offer was made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer was available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") ("QIB Portion"), of which one-third was reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price ("Anchor Investor Portion"), in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion was made available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion was made available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids having been received at or above the Offer Price. Further, not more than 15% of the Net Offer was available for allocation to Non-Institutional Bidders out of which (a) one third of such portion was reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two third of such portion was reserved for applicants with application size of more than ₹1,000,000 and not more than 10% of the Net Offer was available for allocation to Retail Individual Bidders, in accordance with the SEBI ICDR Regulations, subject to valid Bids having been received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders (except Anchor Investors) were required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID (in case of UPI Bidders) (as defined hereinafter), in which case the corresponding Bid Amounts was blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors were not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "Offer Procedure" on page 472 of the Prospectus.

The Bidding for Anchor Investors opened and closed on Monday, July 29, 2024. Our Company received 50 applications from 34 Anchor Investors (including 9 domestic mutual funds through 24 Mutual Fund schemes) for 1,24,56,862 Equity Shares. The Anchor Investor Offer Price was finalized at ₹679 per Equity Share. A total of 1,22,05,912 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹8,28,78,14,248.00.

The Offer received 23,37,372 applications for 96,52,33,918 Equity Shares (prior to rejections) resulting in 63.66 times subscription. The details of the applications received in the Offer from various categories are as under (before rejections):

Table with 7 columns: SR. NO., CATEGORY, NO. OF APPLICATIONS, NO. OF SHARES, RESERVED, NO OF TIMES SUBSCRIPTION, AMOUNT (₹). Rows include Retail Individual Bidders, Non-Institutional Bidders, Employee Investors, and Qualified Institutional Bidders.

Final Demand

A summary of the final demand as per NSE and BSE as on the Bid/Offer Closing Date as at different Bid prices is as under:

Table with 6 columns: SR. NO., BID PRICE, NO. OF EQUITY SHARES, % TO TOTAL, CUMULATIVE TOTAL, CUMULATIVE % OF TOTAL. Shows bid price ranges from 646 to 670 and cumulative totals up to 98,11,21,460 shares.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being the NSE on August 02, 2024.

A. Allotment to Retail Individual Investors (after rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Investors, who have bid at the Cut-Off Price or at the Offer Price of ₹679 per Equity Share, was finalized in consultation with the NSE. This category has been subscribed to the extent of 21.02 times. The total number of Equity Shares Allotted in the Retail Portion is 27,12,431 Equity Shares including spillover of 7 Equity Shares from Employee category to 1,23,292 successful Retail Individual Investors. The category-wise details of the Basis of Allotment are as under:

Table with 9 columns: SR. NO., CATEGORY, NO. OF APPLICATIONS RECEIVED, % OF TOTAL, TOTAL NO. OF EQUITY SHARES APPLIED, % TO TOTAL, NO. OF EQUITY SHARES ALLOTTED PER BIDDER, RATIO, TOTAL NO. OF EQUITY SHARES ALLOTTED. Includes a row for 10862 Allottees from Serial no 2 to 13 Additional 1(one) share.

B. Allotment to Non-Institutional Investors (more than ₹200,000 and up to ₹1,000,000) (after rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (more than ₹200,000 and up to ₹1,000,000), who have bid at the Offer Price of ₹679 per Equity Share or above, was finalized in consultation with the NSE. This category has been subscribed to the extent of 31.84 times. The total number of Equity Shares Allotted in this category is 13,56,215 Equity Shares including spillover of 3 Equity Shares from Employee category to 4,403 successful Non-Institutional Investors (more than ₹200,000 and up to ₹1,000,000). The category-wise details of the Basis of Allotment are as under (Sample):

Table with 9 columns: SR. NO., CATEGORY, NO. OF APPLICATIONS RECEIVED, % OF TOTAL, TOTAL NO. OF EQUITY SHARES APPLIED, % TO TOTAL, NO. OF EQUITY SHARES ALLOTTED PER APPLICANT, RATIO, TOTAL NO. OF EQUITY SHARES ALLOTTED. Includes a row for 213 Allottees from Serial no 2 to 521 Additional 1(one) share.

C. Allotment to Non-Institutional Investors (more than ₹1,000,000) (after rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (more than ₹1,000,000), who have bid at the Offer Price of ₹679 per Equity Share or above, was finalized in

consultation with the NSE. This category has been subscribed to the extent of 47.30 times. The total number of Equity Shares Allotted in this category is 27,12,432 Equity Shares including spillover of 7 Equity Shares from Employee category to 8,806 successful Non-Institutional Investors (more than ₹1,000,000). The category-wise details of the Basis of Allotment are as under (Sample):

Table with 10 columns: SR. NO., CATEGORY, NO. OF APPLICATIONS RECEIVED, % OF TOTAL, TOTAL NO. OF EQUITY SHARES APPLIED, % TO TOTAL, NO. OF EQUITY SHARES ALLOTTED PER APPLICANT, RATIO, TOTAL NO. OF EQUITY SHARES ALLOTTED. Includes a row for 8806 Allottees from Serial no 1 to 1161 Additional 1(one) share.

D. Allotment to Eligible Employees (After Rejections)

The Basis of Allotment to the Eligible Employees, who have bid at the Offer Price of ₹679 per Equity Share# or above, was finalized in consultation with NSE. This category has been subscribed to the extent of ₹0.99 times. 68 equity shares were spilled over to the Net issue portion. The total number of Equity Shares allotted in this category is ₹2,43,826 Equity Shares to ₹1,537 successful applicants. The category-wise details of the Basis of Allotment are as under:

Table with 8 columns: SR. NO., CATEGORY, NO. OF APPLICATIONS RECEIVED, % OF TOTAL, TOTAL NO. OF EQUITY SHARES APPLIED, % TO TOTAL, NO. OF EQUITY SHARES ALLOTTED PER APPLICANT, RATIO, TOTAL NO. OF EQUITY SHARES ALLOTTED. Shows allotment details for 1,537 employees.

E. Allotment to QIBs (after rejections)

Allotment to QIBs, who Bid at the Offer Price of ₹679 per Equity Share or above, has been done on a proportionate basis in consultation with the NSE. This category has been subscribed to the extent of 89.94 times of the Net QIB Portion. As per the SEBI ICDR Regulations, Mutual Funds were allotted 5% of the Equity Shares of the Net QIB Portion available, i.e., 4,06,867 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were allotted the remaining available Equity Shares i.e., 77,30,460 Equity Shares on a proportionate basis. The total number of Equity Shares allotted in the Net QIB Portion is 81,37,327 Equity Shares, which were allotted to 165 successful QIB Bidders. This includes 51 Equity shares spilled over from Employee Category. The category-wise details of the Basis of Allotment are as under:

Table with 9 columns: CATEGORY, FIS/BANKS, MF'S, IC'S, NBFC'S, AIF, FPC, VC'S, TOTAL. Shows allotment to various financial institutions.

F. Allotment to Anchor Investors

Our Company in consultation with the BRLMs, have allocated 1,22,05,912 Equity Shares to 34 Anchor Investors (through 50 Anchor Investor Application Forms) (including 9 domestic Mutual Funds through 24 schemes) at the Anchor Investor Offer Price of ₹679 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Portion.

Table with 8 columns: CATEGORY, FIS/BANKS, MF'S, IC'S, NBFC'S, AIF, FPC, OTHERS, TOTAL. Shows allotment to various financial institutions.

The Board at its meeting held on August 02, 2024 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful applicants. The Allotment Advice-cum-Unblocking Intimations and/ or notices have been dispatched to the addresses of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfers to the Public Offer Account have been issued on August 02, 2024 and payment to non-Syndicate brokers have been issued on August 05, 2024. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares allotted to the successful Allottees have been uploaded on August 05, 2024 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. Our Company has filed the listing application with the NSE and BSE on August 05, 2024. Our Company has received the listing and trading approval from NSE and BSE and the trading will commence on August 06, 2024.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

INVESTORS PLEASE NOTE

The details of the Allotment made will be hosted on the website of the Registrar to the Offer, Link Intime India Private Limited at www.linkintime.co.in All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the first/sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:



Link Intime India Private Limited
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
Tel: +91 810 811 4949, E-mail: akumsdrugs ipo@linkintime.co.in, Website: www.linkintime.co.in
Investor Grievance ID: akumsdrugs ipo@linkintime.co.in, Contact Person: Shanti Gopalkrishnan
SEBI Registration Number: INR00004058

For AKUMS DRUGS AND PHARMACEUTICALS LIMITED

On behalf of the Board of Directors

Place: New Delhi Date: August 05, 2024
Dharamvir Malik
Company Secretary & Compliance Officer

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTUS OF AKUMS DRUGS AND PHARMACEUTICALS LIMITED.

AKUMS DRUGS AND PHARMACEUTICALS LIMITED has filed a Prospectus dated Thursday, August 1, 2024 ("Prospectus") with the Registrar of Companies ("RoC"). The Prospectus is available on the website of the Company at www.akums.in, SEBI at www.sebi.gov.in, the website of the National Stock Exchange of India Limited at www.nseindia.com and the website of the BSE Limited at www.bseindia.com and the respective website of the book running lead managers to the Offer, namely, ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited, at www.icicisecurities.com, www.axiscapital.co.in, www.online.citibank.co.in/html/citigroupglobalscreen1.htm and www.ambit.co. Investors should note that investment in equity shares involves a high degree of risk. For details, refer to the Prospectus filed with the RoC, including the section titled "Risk Factors" on page 28 of the Prospectus.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) outside the United States in offshore transactions as defined in and in compliance with Regulation S and the applicable laws of the jurisdictions where those offers and sales are made, and (b) in the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act. There will be no public offering of securities in the United States.